Free Trial

Kymera Therapeutics (KYMR) Short Interest Ratio & Short Volume

→ Read this before you buy AI stocks (From InvestorPlace) (Ad)
Free KYMR Stock Alerts
$36.01
+1.06 (+3.03%)
(As of 05/20/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Kymera Therapeutics Short Interest Data

Current Short Interest
9,910,000 shares
Previous Short Interest
9,700,000 shares
Change Vs. Previous Month
+2.16%
Dollar Volume Sold Short
$333.17 million
Short Interest Ratio
16.2 Days to Cover
Last Record Date
April 30, 2024
Outstanding Shares
61,358,000 shares
Percentage of Shares Shorted
16.15%
Today's Trading Volume
378,756 shares
Average Trading Volume
692,873 shares
Today's Volume Vs. Average
55%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Kymera Therapeutics ?

Sign up to receive the latest short interest report for Kymera Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

KYMR Short Interest Over Time

KYMR Days to Cover Over Time

KYMR Percentage of Float Shorted Over Time

Kymera Therapeutics Short Interest History

Export to Excel
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/30/20249,910,000 shares $333.17 million +2.2%N/A16.2 $33.62
4/15/20249,700,000 shares $333.58 million +7.1%N/A14.8 $34.39
3/31/20249,060,000 shares $364.21 million +8.8%N/A12 $40.20
3/15/20248,330,000 shares $338.03 million +1.0%N/A10.2 $40.58
2/29/20248,250,000 shares $352.28 million -1.8%N/A9 $42.70
2/15/20248,400,000 shares $314.33 million +1.7%N/A9.4 $37.42
1/31/20248,260,000 shares $270.76 million -4.2%N/A8.9 $32.78
1/15/20248,620,000 shares $242.39 million -4.9%N/A9.3 $28.12
12/31/20239,060,000 shares $230.67 million +4.4%N/A9.4 $25.46
12/15/20238,680,000 shares $226.37 million +12.9%N/A9.9 $26.08
11/30/20237,690,000 shares $159.64 million +3.2%N/A10.3 $20.76
11/15/20237,450,000 shares $134.77 million -8.0%N/A11.2 $18.09
10/31/20238,100,000 shares $94.53 million +10.7%N/A13.9 $11.67
10/15/20237,320,000 shares $92.31 million +0.4%N/A14.2 $12.61
9/30/20237,290,000 shares $101.33 million -1.8%N/A17.9 $13.90
9/15/20237,420,000 shares $141.35 million +3.6%N/A19.7 $19.05
8/31/20237,160,000 shares $136.61 million -2.3%N/A17.1 $19.08
8/15/20237,330,000 shares $143.74 million -3.9%N/A15.5 $19.61
7/31/20237,630,000 shares $166.94 million -5.5%N/A15.3 $21.88
7/15/20238,070,000 shares $178.67 million -0.6%N/A15.5 $22.14
6/30/20238,120,000 shares $186.68 million -2.3%N/A15.2 $22.99
6/15/20238,310,000 shares $229.94 million -10.1%N/A15.5 $27.67
5/31/20239,240,000 shares $272.03 million -2.0%N/A18.8 $29.44
5/15/20239,430,000 shares $281.96 million -2.0%21.3%20.8 $29.90
4/30/20239,620,000 shares $303.41 million -0.2%21.7%21.4 $31.54
4/15/20239,640,000 shares $316.77 million +0.5%21.8%21.4 $32.86
3/31/20239,590,000 shares $284.15 million +2.0%21.7%18.6 $29.63
3/15/20239,400,000 shares $292.62 million -0.6%21.3%17.6 $31.13
2/28/20239,460,000 shares $296.85 million -0.7%21.4%13.2 $31.38
2/15/20239,530,000 shares $314.49 million -1.1%21.7%13.1 $33.00
1/31/20239,640,000 shares $360.34 million +2.4%21.9%12.9 $37.38
1/15/20239,410,000 shares $325.02 million +4.6%21.4%12.3 $34.54
12/30/20229,000,000 shares $224.64 million +11.8%20.5%11.7 $24.96
12/15/20228,050,000 shares $224.60 million +9.8%18.4%10.6 $27.90
11/30/20227,330,000 shares $212.42 million -7.0%16.9%11.7 $28.98
11/15/20227,880,000 shares $236.64 million -5.6%18.1%12.3 $30.03
10/31/20228,350,000 shares $253.34 million +8.4%19.3%12.6 $30.34
10/15/20227,700,000 shares $169.40 million +1.9%18.0%11.6 $22.00
9/30/20227,560,000 shares $164.58 million +10.2%17.9%11.7 $21.77
9/15/20226,860,000 shares $197.29 million +7.7%16.2%9.9 $28.76
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (Ad)

Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!

Click for Zack's full report
8/31/20226,370,000 shares $180.08 million +7.4%15.1%8.9 $28.27
8/15/20225,930,000 shares $200.08 million -3.3%14.8%8.2 $33.74
7/31/20226,130,000 shares $135.04 million -4.1%15.3%8 $22.03
7/15/20226,390,000 shares $148.44 million +10.0%16.0%8 $23.23
6/30/20225,810,000 shares $114.40 million +16.9%14.5%7.5 $19.69
6/15/20224,970,000 shares $70.47 million +1.0%12.4%6.8 $14.18
5/31/20224,920,000 shares $70.21 million -0.2%12.3%7.6 $14.27
5/15/20224,930,000 shares $85.98 million +42.5%12.3%8.4 $17.44
4/30/20223,460,000 shares $108.47 million +6.1%8.7%6.8 $31.35
4/15/20223,260,000 shares $124.01 million +7.6%8.2%8 $38.04
3/31/20223,030,000 shares $128.23 million -3.5%7.6%7.4 $42.32
3/15/20223,140,000 shares $111.97 million +11.4%9.4%8 $35.66
2/28/20222,820,000 shares $112.12 million +8.1%8.4%7.2 $39.76
2/15/20222,610,000 shares $114.14 million +13.5%7.8%6.8 $43.73
1/31/20222,300,000 shares $96.60 million +12.2%7.5%6.4 $42.00
1/15/20222,050,000 shares $84.19 million +3.5%6.0%6.1 $41.07
12/31/20211,980,000 shares $125.71 million +17.2%5.8%7 $63.49
12/15/20211,690,000 shares $93.71 million -0.6%4.9%5.9 $55.45
11/30/20211,700,000 shares $94.38 million +13.3%5.0%5.6 $55.52
11/15/20211,500,000 shares $91.95 million +4.9%4.4%4.9 $61.30
10/29/20211,430,000 shares $84.20 million +0.7%4.4%4.4 $58.88
10/15/20211,420,000 shares $81.22 million -13.9%4.3%4.3 $57.20
9/30/20211,650,000 shares $96.92 million +8.6%5.0%4.5 $58.74
9/15/20211,520,000 shares $98.78 million -10.1%4.6%3.1 $64.99
8/31/20211,690,000 shares $105.02 million -15.5%5.1%3.5 $62.14
8/13/20212,000,000 shares $107.88 million -2.9%6.2%4.2 $53.94
7/30/20212,060,000 shares $123.97 million +5.6%7.1%4.2 $60.18
7/15/20211,950,000 shares $93.83 million -17.4%6.7%4 $48.12
6/30/20212,360,000 shares $114.46 million +30.4%8.1%4.8 $48.50
6/15/20211,810,000 shares $88.40 million -7.7%6.9%4.7 $48.84
5/28/20211,960,000 shares $94.26 million -8.8%7.4%4.5 $48.09
5/14/20212,150,000 shares $97.55 million -9.3%8.2%5 $45.37
4/30/20212,370,000 shares $108.31 million +3.0%9.6%6 $45.70
4/15/20212,300,000 shares $83.47 million +6.5%9.4%6.4 $36.29
3/31/20212,160,000 shares $78.68 million +100.0%8.9%6.7 $36.43
3/15/20211,080,000 shares $60.59 million +3.9%4.4%3.6 $56.10
2/26/20211,040,000 shares $51.58 million -13.3%4.3%4.9 $49.60
2/12/20211,200,000 shares $82.88 million +0.8%5.2%6.5 $69.07
1/29/20211,190,000 shares $76.01 million +8.2%5.2%6.9 $63.87
1/15/20211,100,000 shares $89.43 million No Change4.8%6.7 $81.30

KYMR Short Interest - Frequently Asked Questions

What is Kymera Therapeutics' current short interest?

Short interest is the volume of Kymera Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 9,910,000 shares of KYMR short. Learn More on Kymera Therapeutics' current short interest.

What is a good short interest ratio for Kymera Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KYMR shares currently have a short interest ratio of 16.0. Learn More on Kymera Therapeutics's short interest ratio.

Is Kymera Therapeutics' short interest increasing or decreasing?

Kymera Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 9,910,000 shares, an increase of 2.2% from the previous total of 9,700,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Kymera Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the sector of "medical" compare to Kymera Therapeutics: ADMA Biologics, Inc. (3.82%), Apogee Therapeutics, Inc. (14.00%), Beam Therapeutics Inc. (17.03%), Recursion Pharmaceuticals, Inc. (24.98%), Vericel Co. (9.22%), Sana Biotechnology, Inc. (20.85%), Novavax, Inc. (32.00%), Ginkgo Bioworks Holdings, Inc. (20.84%), Fusion Pharmaceuticals Inc. (4.64%), Inhibrx, Inc. (4.18%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

What does it mean to sell short Kymera Therapeutics stock?

Short selling KYMR is an investing strategy that aims to generate trading profit from Kymera Therapeutics as its price is falling. KYMR shares are trading up $1.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Kymera Therapeutics?

A short squeeze for Kymera Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KYMR, which in turn drives the price of the stock up even further.

How often is Kymera Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KYMR, twice per month. The most recent reporting period available is April, 30 2024.



More Short Interest Resources from MarketBeat

Related Companies:
Short Interest Tools:
This page (NASDAQ:KYMR) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
The ONE AI Stock to own now. (It’s not Nvidia.)
Weiss Ratings
The 2024 Gold Rush: Unleashing Market Potential
Priority Gold
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
Warren Buffett's "mystery stock"
Stansberry Research
This Could be Your “Big Money” AI Moment
InvestorPlace
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest
Elon to Transform U.S. Economy?
Porter & Company